-
Charlie Puth and Ellie Goulding to Headline First Johnnie & Co. Festival in Mumbai
-
ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances
-
Maryland Woman Arrested in Decade-Long Cancer Scam Involving Fake Medical Team
-
Panthers Seek NFC South Lead Against Ravens as Baltimore Ends Skid
-
Dateline appoints Tony Ferguson as Acting Chairman
-
American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities
-
AI Search Engineers Says Longer AI Mode Questions Mean Professional Service Firms Should Answer Full Client Questions Directly on Their Pages
-
Arrive AI's Pro Forma Stockholders' Equity Now Above Nasdaq Minimum Requirement Following Recent Transactions
-
Who Does the Best Rhinoplasty in Sarasota?
-
PodcastOne (NASDAQ:PODC) Launches People Pleasers Podcast hosted by Comedians Leah Rudick and Jessica Michelle Singleton
-
Alset AI Closes Non-Brokered Private Placement Offering
-
Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
-
barq Signs MoU with TenPay Global to Enhance Remittances and Digital Payments in China
-
American Resources Corporation and ReElement Technologies Selected as Part of Winning U.S.-Led Consortium for Kenya's Strategic Mrima Hill Critical Minerals Project
-
Ryde Group Ltd Announces Non-Binding Term Sheet for Proposed Minority Investment in Multi Genius Limited and MOU on Technology Collaboration
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 20
-
Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure
-
The DEA Laid The Trap - And State Marijuana Operators Took The Bait
-
5 Fun Date Night Ideas That Don't Cost a Fortune
-
AsiaFIN Holdings Corp. Appoints Fortune Angel INC as U.S. Reseller Partner to Expand Its Agentic and Robotic Process Automation SaaS Business Across New York and the East Coast
-
What Is the Best Social Media Platform for Peptides?
-
WhalesBot Advances Creativity-Driven AI and Coding Education Through Pubbo AI
-
Karviva Introduces Unwined Alcohol-Free Malbec and Rose Varieties
-
Tidal Wave Auto Spa Opens New Locations in Murfreesboro, Tennessee and Asheville, North Carolina This Week
-
Peoples Bancorp Announces Cash Dividend
-
Jaguar Health, Inc. Announces Reverse Stock Split
-
Kartoon Studios' Beacon Media Partners With Bandai on Tamagotchi's Landmark 30th Anniversary Times Square Celebration
-
First Phosphate and Zeo Energy Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
-
Taylor Bank Announces $125,000 Commitment to Diakonia's Supportive Living Campus Capital Campaign
-
Ondas, Palantir and Regna AI Host Key Defense Technology Leaders to Accelerate the Path from AI Innovation to Fielded Capability
-
Cytta Air Expands Military Contracting Expertise - Appoints Rear Admiral James "Gib" Godwin III to Advisory Board
-
Closing a Business with Payroll Taxes Owed - Clear Start Tax Explains the Trust Fund Recovery Penalty
-
Commonhold Explained: How New Leasehold Ban Changes Property Ownership in England and Wales
-
Factory Worker Dies in Rare Rectal Explosion Incident in Czechia
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
-
Decoding UNFCCC Legal Language: The Hierarchy of Verbs in Climate Negotiations
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive year. Moderna was recognized for its commitment to continuous innovation and a culture that reflects the values of its employees.
"We are honored to be recognized by Science as a top employer, with this year marking the eleventh consecutive year we have been named to this important list," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our team continues to execute our strategy, advancing our pipeline of mRNA medicines and staying focused on our commitment to patients. I am proud that Moderna remains a company where our team members can build purposeful careers."
In 2025, Moderna received approval for its third product, mNEXSPIKE®, a new vaccine against COVID-19 for use in all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factors. As its product portfolio grows, Moderna has continued to invest in its global network of advanced manufacturing hubs in Australia, Canada and the United Kingdom, which strengthen pandemic readiness by maximizing geographic coverage and minimizing response times. As part of Moderna's ongoing commitment to social responsibility, the Company also marked the third anniversary of the Moderna Charitable Foundation and issued its fourth annual Impacting Human Health Report.
"At Moderna, we are bringing together people and technology to change what's possible in medicine," said Tracey Franklin, Chief People and Digital Technology Officer of Moderna. "Our teams are constantly adapting, learning and applying new tools, like AI and robotics, in ways to drive innovation and create meaningful impact for years to come."
For more than 20 years, Science has surveyed its readership to identify and celebrate the top 20 pharmaceutical and biotechnology companies with the best reputation as employers. The 2025 survey's findings are based on approximately 5,500 completed surveys from readers of Science, and other survey invitees. A vast majority of the survey participants came from North America (66%), Europe (20%) and Asia/Pacific Rim (9%). Most (97%) of the respondents worked in biotechnology, biopharmaceutical and pharmaceutical companies.
For the complete feature along with individual company rankings, please visit: https://www.science.org/content/article/2025-s-top-employers-innovation-ai-and-policy-biotech-pharma
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including pioneering work on COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Moderna Contacts
Media:
Chris Ridley
Head, Global Media Relations
+1 617-800-3651
[email protected]
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
S.Jackson--AT